Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of January 2021, with a specific transaction notification dated January 7, 2021. The filing serves as a report of a transaction involving a Person Discharging Managerial Responsibilities (PDMR) under the Securities Exchange Act of 1934.
Key Financial Metrics
This filing is a transaction notification and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for these items.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a specific insider transaction rather than comparative financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly reports a single acquisition event.
Important Facts for Investors
- Transaction Type: Acquisition of American Depositary Shares (ADSs) within an Executive Supplemental Savings Plan account.
- Executive Involved: Dr. H Barron, Chief Scientific Officer and President, R&D.
- Transaction Volume: 1,084.913 ADSs.
- Transaction Price: $38.07 per ADS.
- Date and Venue: Executed on January 7, 2021, on the New York Stock Exchange (XNYS).